Lipella shareholders approve reverse stock split authorization at annual meeting

LIPELLA PHARMACEUTICALS INC.

All seven director nominees elected (including CEO Jonathan Kaufman); broker non-votes of 1,703,278.
Reverse stock split authorized (3,881,533 for, 407,381 against); board may implement up to 1:150 within one year.
Ratification of auditor Urish Popeck & Co. for FY2024 ratified with 4,232,289 votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.